Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1.(Previously presented.) A compound of formula I:



I

wherein:

A is a moiety of formula II:



II

D is oxygen or sulfur;

E is a single bond, oxygen, sulfur, or NR^3;

Ar^1 is a 5- or 6-membered aromatic heterocyclic ring having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or

Ar^1 is phenyl;

Ar^2 is a 5- or 6-membered aromatic heterocyclic ring having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or

Ar^2 is phenyl, or

Ar^2 is an 8- or 9-, or 10-membered fused aromatic carbocyclic ring or fused aromatic heterocyclic ring having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or an 8- or 9-, or 10-membered aromatic carbocyclic ring;

the rings Ar^1 and Ar^2 are substituted with 0, 1, 2 or 3 substituents selected from: halogen, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, CN, NO_2, CF_3, NR^1R^2, $CH_2NR^1R^2$, OR^2, CH_2OR^2 or CO_2R^3;

R^1 and R^2 at each occurrence are independently selected from hydrogen, C_{1-4}alkyl, aryl, heteroaryl, $C(O)R^3$, $C(O)NHR^3$, CO_2R^3 or SO_2R^3, or

R^1 and R^2 in combination is $-(CH_2)_jG(CH_2)_k-$ wherein G is oxygen, sulfur, NR^3, or a bond;

a, b and c are each 1;

j is 2, 3 or 4;

k is 0, 1 or 2, and

R^3 at each occurrence is independently selected from hydrogen, C_{1-4}alkyl, aryl, or heteroaryl;

or a diastereoisomer, enantiomer or pharmaceutically-acceptable salt thereof.

2. (Original) A compound according to Claim 1, wherein D is oxygen.

3. (Original) A compound according to Claim 2, wherein E is a single bond.

4. (Original) A compound according to Claim 2, wherein E is oxygen or NR^3.

5. (Canceled.)

6. (Original) A compound of Claim 1, wherein

Ar^1 is a 5- or 6-membered aromatic heterocyclic ring having 1 or 2 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or

Ar^1 is phenyl,

or a diastereoisomer, enantiomer or pharmaceutically-acceptable salt thereof.

7. (Original) A compound according to Claim 6 wherein Ar^1 is a benzene ring, furan ring or thiophene ring.

8. (Original) A compound according to Claim 1, wherein

Ar^2 is a 5- or 6-membered aromatic heterocyclic ring having 1 or 2 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or a phenyl,

or a diastereoisomer, enantiomer or pharmaceutically-acceptable salt thereof.

9. (Original) A compound according to Claim 8, wherein Ar^2 is a benzene ring, furan ring, thiophene ring, or pyridine ring.

10. (Original) A compound according to Claim 1, wherein

the $-EAr^2$ and the C(=D)A moieties on Ar^1 are positioned in a 1,3-relationship relative to each other;

or a diastereoisomer, enantiomer or pharmaceutically-acceptable salt thereof.

11. (Previously presented.) A compound according to Claim 1, wherein Ar^1 or Ar^2 is substituted with 0 or 1 substituents selected from: halogen, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, CN, NO_2, NR^1R^2, $CH_2NR^1R^2$, OR^2, CH_2OR^2, CO_2R^3 or CF_3;

or a diastereoisomer, enantiomer or pharmaceutically-acceptable salt thereof.

12-13.(Canceled.)

14.(Previously presented.) A compound according to Claim 1, having the groups $-EAr^2$ and -C(=O)A, positioned in a 1,3-relationship relative to each other and wherein Ar^2 has 0 or 1 substituents selected from: halogen, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, CN, NO_2, NR^1R^2, $CH_2NR^1R^2$, OR^2, CH_2OR^2, CO_2R^3 or CF_3;

or a diastereoisomer, enantiomer or pharmaceutically-acceptable salt thereof.

15-18. (Canceled.)

19. (Previously presented.) A method of treatment of psychotic disorders, intellectual impairment disorders, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, mania or manic depression, Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, pain, or ulcerative colitis which method comprises administering a therapeutically effective amount of a compound as defined in Claim 1.

20.(Previously presented) A pharmaceutical composition comprising a compound of formula I, as defined in claim 1, together with at least one pharmaceutically-acceptable excipient or diluent.

21-23. (Canceled.)